Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735095 · ClinicalTrials.gov registry record · Phase 1
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03735095 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT03735095, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes. Photodynamic therapy consists of injecting a light sensitive drug called a photosensitizer, such as porfimer sodium, into the vein, waiting for it to accumulate in the tumor, and then activating it with a red laser light. Giving photodynamic therapy with Porfimer sodium may reduce the tumor size in patients with lung cancer.
Interventions
- DRUG Porfimer Sodium
- PROCEDURE Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2024-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03735095
The ClinicalTrials.gov registry entry for NCT03735095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Porfimer Sodium is the first listed.
NCT03735095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03735095 about?
NCT03735095 is a clinical study titled "Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer". This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes. Photodynamic therapy consists of injecting a light sensitive drug called a photosensitizer, such ...
What is the current status of trial NCT03735095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-02-12. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT03735095?
The interventions under investigation include: Porfimer Sodium (DRUG), Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT03735095?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.